Back to Search Start Over

Propofol rescues voltage-dependent gating of HCN1 channel epilepsy mutants.

Authors :
Kim ED
Wu X
Lee S
Tibbs GR
Cunningham KP
Di Zanni E
Perez ME
Goldstein PA
Accardi A
Larsson HP
Nimigean CM
Source :
Nature [Nature] 2024 Aug; Vol. 632 (8024), pp. 451-459. Date of Electronic Publication: 2024 Jul 31.
Publication Year :
2024

Abstract

Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels <superscript>1</superscript> are essential for pacemaking activity and neural signalling <superscript>2,3</superscript> . Drugs inhibiting HCN1 are promising candidates for management of neuropathic pain <superscript>4</superscript> and epileptic seizures <superscript>5</superscript> . The general anaesthetic propofol (2,6-di-iso-propylphenol) is a known HCN1 allosteric inhibitor <superscript>6</superscript> with unknown structural basis. Here, using single-particle cryo-electron microscopy and electrophysiology, we show that propofol inhibits HCN1 by binding to a mechanistic hotspot in a groove between the S5 and S6 transmembrane helices. We found that propofol restored voltage-dependent closing in two HCN1 epilepsy-associated polymorphisms that act by destabilizing the channel closed state: M305L, located in the propofol-binding site in S5, and D401H in S6 (refs.  <superscript>7,8</superscript> ). To understand the mechanism of propofol inhibition and restoration of voltage-gating, we tracked voltage-sensor movement in spHCN channels and found that propofol inhibition is independent of voltage-sensor conformational changes. Mutations at the homologous methionine in spHCN and an adjacent conserved phenylalanine in S6 similarly destabilize closing without disrupting voltage-sensor movements, indicating that voltage-dependent closure requires this interface intact. We propose a model for voltage-dependent gating in which propofol stabilizes coupling between the voltage sensor and pore at this conserved methionine-phenylalanine interface in HCN channels. These findings unlock potential exploitation of this site to design specific drugs targeting HCN channelopathies.<br /> (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)

Details

Language :
English
ISSN :
1476-4687
Volume :
632
Issue :
8024
Database :
MEDLINE
Journal :
Nature
Publication Type :
Academic Journal
Accession number :
39085604
Full Text :
https://doi.org/10.1038/s41586-024-07743-z